Cancer care requires a personalized, team-based approach. Collaboration among researchers, providers and patients is crucial to advancing treatment.
Where I see patients (2)
My reviews
Selected research
-
Phase II Study of Pexidartinib Plus Sirolimus in Unresectable Malignant Peripheral Nerve Sheath Tumors Identifies M2 Macrophage Activation.
JCO oncology advances
-
The Decline and Fall of the Current Chemotherapy Paradigm in Soft Tissue Sarcoma.
Cancers
-
Human chorionic gonadotropin-secreting osteosarcoma.
BMJ case reports
Clinical trials
Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma
Safety and tolerability will be reported as the percentage of the first 6 participants (the safety-lead in participants) who received at least one dose of study treatment with any reported treatment-emergent adverse events (TEAEs)...
Recruiting
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarc...
The primary objective is to compare the primary endpoint of PFS in subjects treated with the arginine degrading enzyme ADI-PEG 20 plus Gem and Doc (ADIGemDoc) or PBO plus Gem and Doc (PBOGemDoc) in the 2nd or 3rd line setting usin...
Recruiting
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients Wit...
Will be compared between the treatment arms (doxorubicin + pembrolizumab versus [vs] doxorubicin alone). The comparison of PFS between treatment arms will be done using a stratified (on Eastern Cooperative Oncology group performan...
Recruiting
4.9